CALCITRIOL ORAL PULSE THERAPY IN CHILDREN WITH RENAL OSTEODYSTROPHY

被引：13

作者：

CANO, F

DELUCCHI, A

WOLFF, E

RODRIGUEZ, E

FUENTES, A

机构：

[1] Division of Paediatric Nephrology, University of Chile, Luis Calvo Mackenna Children's Hospital, Providencia, Santiago

[2] Department of Paediatrics, University of Chile, Luis Calvo Mackenna Children's Hospital, Providencia, Santiago

来源：

PEDIATRIC NEPHROLOGY | 1995年 / 9卷 / 05期

关键词：

RENAL OSTEODYSTROPHY; CALCITRIOL PULSES; PARATHYROID HORMONE; CHRONIC RENAL FAILURE; VITAMIN-D;

D O I：

10.1007/BF00860951

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

A 6-month protocol of oral pulse calcitriol was used in nine uraemic children (2-14 years old) on dialysis who presented with renal osteodystrophy. Calcitriol was administered twice a week, 4 mu g per dose for patients over 30 kg and 3 mu g for patients less than 30 kg. Plasma levels of parathyroid hormone, calcium, phosphorus and alkaline phosphatase were carefully controlled during the study. Parathyroid hormone levels decreased by 68% and 56% by the 2nd and 6th months of treatment in seven patients, while they remained unchanged in two patients with focal segmental glomerulosclerosis and massive proteinuria. Eight hypercalcaemic episodes from 77 determinations were observed, all of them recovered after 1 week of vitamin D withdrawal. We conclude that oral calcitriol pulse therapy is a good alternative for renal osteodystrophy in uraemic children. Careful monitoring of plasma parathyroid hormone and calcium is needed during follow-up when using this approach in paediatric patients.

引用

页码：606 / 608

页数：3

共 12 条

[1]

Coburn J.W., Slatopolsky E., Vitamin D, parathyroid hormone and renal osteodystrophy, The kidney, pp. 1657-1729, (1986)

[2]

Malluche H.H., Faugere M.C., Effects of 1,25(OH)2D3 administration on bone in patients with renal failure, Kidney Int, 38, pp. 48-53, (1990)

[3]

Coburn J.W., Renal osteodystrophy, Kidney International, 17, pp. 677-679, (1980)

[4]

Salusky I.B., Coburn J.W., Brill J., Foley J., Slatopolsky E., Fine R., Goodman W., Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD, Kidney Int, 33, pp. 975-982, (1988)

[5]

Silver J., Naveh-Many T., Mayer H., Schmelzer H., Popovtzer M., Regulation by vitamin D metabolites of parathyroid hormone gene in vivo by the rat, J Clin Invest, 78, pp. 1296-1301, (1986)

[6]

Rusell J., Lettieri D., Sherwood L.M., Suppression by 1,25(OH)2D3 of transcription of the parathyroid hormone gene, Endocrinology, 119, pp. 2864-2866, (1986)

[7]

Saiusky I.B., Fine R.N., Hooshang K., Gold R., Paunier L., Goodman W., Brill J., Gilli G., Slatopolsky E., Coburn J., “High dose” calcitriol for control of renal osteodystrophy in children on CAPD, Kidney International, 32, pp. 89-95, (1987)

[8]

Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K., Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25dihydroxycholecalciferol in uremic patients, J Clin Invest, 74, pp. 2136-2143, (1984)

[9]

Tsukamoto Y., Nomura M., Takahashi Y., Takagi Y., Yoshida A., Nagaoka T., Togashi K., Kikawada R., Marumo F., The “oral 1,25-dihydroxyvitamin D pulse therapy” in hemodialysis patients with severe secondary hyperparathyroidism, Nephron, 57, pp. 23-28, (1991)

[10]

Martin K., Ballal S., Domoto D., Blalock S., Weindel M., Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on CAPD: preliminary observations, Am J Kidney Dis, 19, pp. 540-545, (1992)

← 1 2 →